Could it be that lobbyists from large pharmaceutical companies are putting pressure on the government to prevent the Israeli medical cannabis market from taking off?
Israel’s attitude toward medical cannabis is schizophrenic.
On one hand, it is probably the most developed nation in the world when it comes to innovation in the field. Israel, one of the few countries where it is completely legal to engage in clinical research, has develop new and innovative ways to deliver the medicinal substance in cannabis. Inhalers, creams, pills and oils make it easier for people who need cannabis to administer it. And researchers have perfected measurement of dosages so that the patient receives the exact amount he or she needs, and is not dependent on fluctuating qualities.
In April, the government will also become one of the few, if not the first, government to sponsor a conference that deals with uses of medicinal cannabis. Israel has also taken steps toward decriminalization. And more than 30,000 Israeli patients now receive cannabis through the health funds for medicinal use.
On the other hand, bureaucracy within the Health Ministry has forced tens of thousands of additional patients suffering from a wide range of ailments that can be treated with medicinal cannabis to wait more than a year to receive what they need. In the meantime, they are forced to take conventional drugs such as opioids and steroids, which are addictive and dangerous.
And the government is also dragging its feet with regard to export of medicinal cannabis, a multi-billion-shekel market that could generate thousands of jobs and millions of shekels in tax revenue.
Dozens of firms have received permits to set up farms to grow medicinal cannabis, and a sweeping reform was instituted to regulate the growing and marketing of the substance. Since the permits were issued last year, tens of millions of dollars have been invested by both local and international firms to prepare for growing and marketing cannabis for medicinal use. The Agriculture Ministry declared medicinal cannabis to be a legitimate industry, which opens up forms of government aid to growers.
But until the government approves export, Israel’s tremendous know-how and economic potential will not be realized. The highly regulated local market is simply too small to support Israel’s tremendous potential.
The cabinet was slated to vote on Thursday on opening up medicinal cannabis to export, but the vote was delayed at the last minute. Public Security Minister Gilad Erdan is demanding more than NIS 200 million to create new positions in the Israel Police that will be responsible for making sure that cannabis is sold purely for medicinal purposes and to put in place security arrangements related to the transport of the substance abroad. The Treasury for its part has so far refused to provide the requisite funding from the 2019 budget.
So while the government gave dozens of firms permits to build cannabis farms, the entire medicinal cannabis market is stuck because there is no way of selling most of the finished product until the government approves exports.
Why did the government approve the building of these farms if it had no intention of allowing growers to export? Is the government schizophrenic? It is no secret that medicinal cannabis is effective for the treatment of a wide range of ailments from skin diseases and glaucoma to autism and ALS.
A study published in November by the University of New Mexico, for instance, found that cannabis is effective in reducing opioid use. Opioid overdose is the leading cause of preventable deaths in the US.
Cannabis has also been found to reduce the use of other prescription drugs.
Could it be that lobbyists from large pharmaceutical companies are putting pressure on the government to prevent the Israeli medical cannabis market from taking off? Prescription drug sellers clearly have an interest in preventing marketing of medical cannabis that would lower demand for conventional drugs.
The question is whether the government will continue to exhibit schizophrenia (by the way, the cannabis-derived chemical cannabidiol is thought to offer relief to schizophrenics); or will the government do what is right not just for business, innovation and the economy but also for millions of patients suffering from diseases readily treatable with cannabis?
Source: Jerusalem Post
The author rightly questions whether there are forces at work besides selfless compassion for the suffering, and pure hard science. In fact, ‘big pharma’ may have paid trolls online to comment on articals such as his.
Look at the 3 comments posted to his article all within 7 minutes of each other…
Pure, hard science:
A brain and mental health researcher is strongly arguing that there is no link between cannabis use and developing schizophrenia.
Matthew Hill, PhD of the University of Calgary’s (Canada) Hotchkiss Brain Institute, writing in Nature, notes that there is no concrete evidence of a connection between cannabis and schizophrenia. As he points out, the incidence of schizophrenia has not gone up since the 1960s, when marijuana use became popular in the U.S. and Europe. In addition, countries in which a large segment of the population uses cannabis do not have higher schizophrenia rates.
However, Hill concedes that marijuana use might bring on schizophrenia earlier in those who are predisposed to the condition.
One of the first studies to indicate a link between marijuana and schizophrenia came out in 1987 in Sweden. It found Army soldiers who used cannabis were found to have a higher incidence of schizophrenia. However, Hill points out that the study found that high doses of THC, the active ingredient, can cause acute psychosis, which then goes away.
Many have mistakenly believed, he argues, that the psychosis is permanent. And no other studies have come to this conclusion.
A recent Harvard University study also found no association between cannabis use and schizophrenia.
The researchers concluded that the results of the current study, “both when analyzed using morbid risk and family frequency calculations, suggest that having an increased familial risk for schizophrenia is the underlying basis for schizophrenia in these samples — not the cannabis use.
“While cannabis may have an effect on the age of onset of schizophrenia it is unlikely to be the cause of illness,” said the researchers, who were led by Ashley C. Proal from Harvard Medical School.